Chimeric protein toxins for expression by therapeutic bacteria
OwnerDavid Gordon Bermudesinventor
Life of this patent
Estimating the term…
Abstract
Bacteria with tumor-targeting capability express, surface displayed, secreted and/or released modified chimeric therapeutic proteins with enhanced therapeutic activity against a neoplastic tissue including solid tumors, lymphomas and leukemias. The bacteria may be attenuated, non-pathogenic, low pathogenic or a probiotic. The chimeric proteins may be protease sensitive and may optionally be further accompanied by co-expression of a secreted protease inhibitor as a separate molecule or as a fusion.
Claims18
A chimeric peptide comprising a functional cytolethal distending toxin comprising a C-terminal fusion of three cytolethal distending toxin subunits, and a distinct nuclear localization signal separated by a flexible linker from the three cytolethal distending toxin subunits, the chimeric peptide being terminated with a cysteine, wherein the chimeric peptide is antineoplastic.
An antineoplastic chimeric peptide comprising a C-terminal fusion of a Salmonella cytolethal distending toxin subunit and at least one additional cytolethal distending toxin subunit, and a nuclear localization signal from apoptin, separated from the C-terminal fusion by a flexible peptide linker, the chimeric peptide being a functional cytoletal distending toxin and being terminated with a cysteine.
Dependencies are inferred from the claim text.